News
According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...
Pharmaceutical Technology on MSN6d
Sanofi to acquire Vicebio’s share capital for $1.15bn upfrontSanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.
Khaleej Times on MSN6d
France's Sanofi To Acquire Biotech Firm Vicebio For $1.15 BillionFrench pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...
Sanofi and Kling Bio have entered into a partnership aimed at accelerating the discovery of neutralising antibodies. The ...
Dealbreaker on MSN5d
Sanofi Extends Respiratory Vaccines Reach With $1.15B Acquisition of Clinical-Stage VicebioThe deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.
Investing News Network on MSN4d
Biotech and Pharma Market Update: Q2 2025 in ReviewThe second quarter of 2025 was a period of dynamic evolution within the biotech and pharma sectors. Critical factors like ...
French pharmaceutical and healthcare company Sanofi has agreed to buy the British biotechnology firm Vicebio for up to $1.6bn ...
5d
Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...
Plus: Meme mania returns ahead of big tech earnings; ASIC chief to warn banks and boards over risky AI use; Microsoft names ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback